พื้นที่โฆษณา

/DISREGARD RELEASE: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./

PR Newswire

พีอาร์ นิวส์ไวร์

ภาษาไทย| English
Like This Page?
PR Newswire - /DISREGARD RELEASE: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./
PR Newswire Jun 12, 25

Share This Page :

We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer, issued 12-Jun-2025 over PR Newswire.

Source : CISION PR Newswire - /DISREGARD RELEASE: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ https://www.prnasia.com/story/archive/4709016_AE09016_0

The information provided in this article was created by CISION PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thai PR News.

Comment

พื้นที่โฆษณา